Worldwide demand for intravenous iron drugs has been registering excellent growth and remained immune to the global recession, according to a new report by Global Industry Analysts Inc.
The IV iron drugs market is expected to grow, the report says, because of an increase in the end-stage renal disease population, in addition to increased consumption of iron by each patient. The overall IV iron market displays huge business opportunities primarily due to the increasing hemodialysis patient population, limitations of other iron replacement therapies and the scope for innovation.
Players profiled in the report include AMAG Pharmaceuticals Inc, Fresenius Medical Care AG & Co. KGaA, Galenica Ltd., Vifor Pharma Ltd, Luitpold Pharmaceuticals Inc, American Regent Inc, Pharmacosmos A/S, Rockwell Medical Technologies Inc, Sanofi-Aventis U.S. LLC, Syner-Med (Pharmaceutical Products) Ltd, and Watson Pharmaceuticals Inc.
The report titled “Intravenous (IV) Iron Drugs: A Global Market Report” is available at www.strategyr.com/Intravenous_IV_Iron_Drugs_Market_Report.asp